Results for relaps translation from Slovak to English

relaps
relapse

relaps -
table 2

svr12 relaps
svr12

relaps %(n/n)
relapse %(n/n)

relaps po liečbe
post-treatment relapse

mali relaps po liečbe
failed to respond or relapsed following treatment with conventional chemotherapy

relaps/ refraktérna ph+ all:
relapsed/ refractory ph+ all:

relaps- remitujúca roztrúsená skleróza
relapsing- remitting multiple sclerosis

relaps po ukončení liečby 1 2a
post-treatment relapse 1 2a

25 relaps - sekundárne trieda orgánových
25 systemorganclass

relaps-remitujúca roztrúsená skleróza (rr-ms)
relapsing-remitting multiple sclerosis (rr-ms)

virologické zlyhanie (relaps a zlyhanie počas liečby)
virologic failure (relapse and on-treatment failure)

relaps sm, závraty*, hypoestézia, parastézia, tremor, dysgeúzia
ms relapse, dizziness*, hypoaesthesia, paraesthesia, tremor, dysgeusia*

poškodenie cns sa môže prejaviť v priebehu záchvatu ms (relaps).
the damage to the cns can occur within an ms attack (relapse).

relaps po virologickej odpovedi na konci liečby u populácie s rýchlou virologickou odpoveďou
relapse of virological response at the end of treatment for rapid virological response population

neurologické hodnotenia boli vykonávané každých 12 týždňov a v období podozrenia na relaps.
neurological evaluations were performed every 12 weeks and at times of suspected relapse.

pac. s b-cll ktorí nereagovali alebo mali relaps po liečbe konvenčnou chemoterapiou
b-cll pts who had failed to respond or relapsed following treatment with conventional chemotherapy

tecfidera sa používa na liečbu relaps-remitujúcej sklerózy multiplex (sm).
tecfidera is used to treat relapsing-remitting multiple sclerosis (ms).

2/ 3 interferónom, alebo s rýchlo sa rozvíjajúcou vážnou relaps- remitujúcou sm.
the committee decided that tysabri’ s benefits are greater than its risks as single disease modifying therapy in highly active relapsing remitting ms for patients with high disease activity despite treatment with a beta-interferon, or with rapidly evolving severe relapsing remitting ms.

Účinnosť na relaps-remitujúcu roztrúsenú sklerózu sa preukázala pre liečbu počas prvých dvoch rokov.
for relapsing-remitting ms, efficacy has been demonstrated for therapy for the first two years.